Skip to content
BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Opthea Ltd. CKDXF

7 fiscal years on record · USD · FY2024 reported · SEC filings only
$25,000
▼ 80.0% YoY
$-162.8M
$-158.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The principal activity of Opthea Limited is to research and develop novel therapeutic products based on targeting Vascular Endothelial Growth Factors (VEGF) C, D and R3. Opthea's lead asset, sozinibercept, was being developed as a novel, first-in-class VEGF-C/D 'trap' inhibitor designed to be used in combination with standard-of-care anti-VEGF-A therapies to improve vision in wet AMD patients, many of whom respond sub-optimally or become refractory to existing therapies. In March 2025 the company announced the Phase 3 trials did not meet their primary endpoints. Since March of 2025 the company has been closing all clinical, manufacturing, and regulatory activities associated with the Wet AMD program and exiting all contracts related to the clinical trials.

Written from the business description in Opthea Limited's annual report to the U.S. Securities and Exchange Commission, filed 15 September 2025. Every sentence was checked against that document before publication.

Growth

USD 25,000.00
Revenue, FY2024 · full 7-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.0 · Net income -162.8
-100M-200M
201820212024
Compound annual growth
−34.9%
−15.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −15.8% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -623048.0%
-200000%-400000%-600000%
201820212024
ROE
FY2021 · ROE -101.3%
-50%-100%
201820212024
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

USD 0.00
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -158.7
-100M-200M
201820212024

Total assetsUSD 56.8M
CashUSD 48.4M
Current ratio0.22×

Not available: we don't have the total debt figure for this period.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CKDXF, 7-year financial record
Metric 2024202320222021202020192018
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.2−0.2−0.2−0.1◌◌◌
EBITDA $B◌◌◌◌◌◌◌
Income tax $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Net income $B−0.2−0.2−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.2−0.2−0.1−0.1−0.0−0.0−0.0
EPS, diluted $−0.13−0.35−0.32−0.26−0.14◌◌
Dividend / sh $◌◌◌◌◌◌◌
Payout %−0−0−0−0−0——
ROE %———−101.3−50.4−33.5−68.4

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 26 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 13 checks were skipped: EPS is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onOTC market
Incorporated inoutside the United States — SEC code C3
Fiscal year endsJune 30
SEC categoryemerging growth company
Data on record since2018

Share this section

Download image